215 related articles for article (PubMed ID: 36708807)
1. The Integrative Studies on the Functional A-to-I RNA Editing Events in Human Cancers.
Wu S; Fan Z; Kim P; Huang L; Zhou X
Genomics Proteomics Bioinformatics; 2023 Jun; 21(3):619-631. PubMed ID: 36708807
[TBL] [Abstract][Full Text] [Related]
2. ADeditome provides the genomic landscape of A-to-I RNA editing in Alzheimer's disease.
Wu S; Yang M; Kim P; Zhou X
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33401309
[TBL] [Abstract][Full Text] [Related]
3. Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers.
Wang Y; Xu X; Yu S; Jeong KJ; Zhou Z; Han L; Tsang YH; Li J; Chen H; Mangala LS; Yuan Y; Eterovic AK; Lu Y; Sood AK; Scott KL; Mills GB; Liang H
Genome Res; 2017 Jul; 27(7):1112-1125. PubMed ID: 28411194
[TBL] [Abstract][Full Text] [Related]
4. The Cancer Editome Atlas: A Resource for Exploratory Analysis of the Adenosine-to-Inosine RNA Editome in Cancer.
Lin CH; Chen SC
Cancer Res; 2019 Jun; 79(11):3001-3006. PubMed ID: 31015229
[TBL] [Abstract][Full Text] [Related]
5. Clinical Relevance of Noncoding Adenosine-to-Inosine RNA Editing in Multiple Human Cancers.
Gu T; Fu AQ; Bolt MJ; White KP
JCO Clin Cancer Inform; 2019 Jun; 3():1-8. PubMed ID: 31162949
[TBL] [Abstract][Full Text] [Related]
6. ADAR1-dependent miR-3144-3p editing simultaneously induces MSI2 expression and suppresses SLC38A4 expression in liver cancer.
Kim HS; Na MJ; Son KH; Yang HD; Kim SY; Shin E; Ha JW; Jeon S; Kang K; Moon K; Park WS; Nam SW
Exp Mol Med; 2023 Jan; 55(1):95-107. PubMed ID: 36599932
[TBL] [Abstract][Full Text] [Related]
7. The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers.
Han L; Diao L; Yu S; Xu X; Li J; Zhang R; Yang Y; Werner HMJ; Eterovic AK; Yuan Y; Li J; Nair N; Minelli R; Tsang YH; Cheung LWT; Jeong KJ; Roszik J; Ju Z; Woodman SE; Lu Y; Scott KL; Li JB; Mills GB; Liang H
Cancer Cell; 2015 Oct; 28(4):515-528. PubMed ID: 26439496
[TBL] [Abstract][Full Text] [Related]
8. The role of A-to-I RNA editing in cancer development.
Xu X; Wang Y; Liang H
Curr Opin Genet Dev; 2018 Feb; 48():51-56. PubMed ID: 29127844
[TBL] [Abstract][Full Text] [Related]
9. When MicroRNAs Meet RNA Editing in Cancer: A Nucleotide Change Can Make a Difference.
Wang Y; Liang H
Bioessays; 2018 Feb; 40(2):. PubMed ID: 29280160
[TBL] [Abstract][Full Text] [Related]
10. A-to-I RNA editing of BLCAP lost the inhibition to STAT3 activation in cervical cancer.
Chen W; He W; Cai H; Hu B; Zheng C; Ke X; Xie L; Zheng Z; Wu X; Wang H
Oncotarget; 2017 Jun; 8(24):39417-39429. PubMed ID: 28455960
[TBL] [Abstract][Full Text] [Related]
11. Adenosine-to-inosine RNA editing meets cancer.
Dominissini D; Moshitch-Moshkovitz S; Amariglio N; Rechavi G
Carcinogenesis; 2011 Nov; 32(11):1569-77. PubMed ID: 21715563
[TBL] [Abstract][Full Text] [Related]
12. ADAR1 and MicroRNA; A Hidden Crosstalk in Cancer.
Cho CJ; Myung SJ; Chang S
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28398248
[TBL] [Abstract][Full Text] [Related]
13. Altered editing level of microRNAs is a potential biomarker in lung adenocarcinoma.
Maemura K; Watanabe K; Ando T; Hiyama N; Sakatani T; Amano Y; Kage H; Nakajima J; Yatomi Y; Nagase T; Takai D
Cancer Sci; 2018 Oct; 109(10):3326-3335. PubMed ID: 30022565
[TBL] [Abstract][Full Text] [Related]
14. RNA editing enzyme ADAR1 controls miR-381-3p-mediated expression of multidrug resistance protein MRP4 via regulation of circRNA in human renal cells.
Omata Y; Okawa M; Haraguchi M; Tsuruta A; Matsunaga N; Koyanagi S; Ohdo S
J Biol Chem; 2022 Aug; 298(8):102184. PubMed ID: 35753353
[TBL] [Abstract][Full Text] [Related]
15. GPEdit: the genetic and pharmacogenomic landscape of A-to-I RNA editing in cancers.
Ruan H; Li Q; Liu Y; Liu Y; Lussier C; Diao L; Han L
Nucleic Acids Res; 2022 Jan; 50(D1):D1231-D1237. PubMed ID: 34534336
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA Editing Detection and Function: A Combined In Silico and Experimental Approach for the Identification and Validation of Putative Oncogenic Targets.
Tassinari V; Cesarini V; Silvestris DA; Scafidi A; Cucina L; Gallo A
Methods Mol Biol; 2021; 2181():253-267. PubMed ID: 32729085
[TBL] [Abstract][Full Text] [Related]
17. RNA editing independently occurs at three mir-376a-1 sites and may compromise the stability of the microRNA hairpin.
Gallego A; Hartasánchez DA; Brasó-Vives M; Garcia-Ramallo E; Lopez-Valenzuela M; Baena N; Guitart M; Fernández-Bellon H; Kondova I; Bontrop R; Kawahara Y; Espinosa-Parrilla Y
Gene; 2017 Sep; 628():109-116. PubMed ID: 28710037
[TBL] [Abstract][Full Text] [Related]
18. The adaptive potential of RNA editing-mediated miRNA-retargeting in cancer.
Tassinari V; Cesarini V; Silvestris DA; Gallo A
Biochim Biophys Acta Gene Regul Mech; 2019 Mar; 1862(3):291-300. PubMed ID: 30605729
[TBL] [Abstract][Full Text] [Related]
19. ADAR regulates APOL1 via A-to-I RNA editing by inhibition of MDA5 activation in a paradoxical biological circuit.
Riella CV; McNulty M; Ribas GT; Tattersfield CF; Perez-Gill C; Eichinger F; Kelly J; Chun J; Subramanian B; Guizelini D; ; Alper SL; Pollak MR; Sampson MG; Friedman DJ
Proc Natl Acad Sci U S A; 2022 Nov; 119(44):e2210150119. PubMed ID: 36282916
[No Abstract] [Full Text] [Related]
20. Identification and Analysis of RNA Editing Events in Ovarian Serous Cystadenoma Using RNA-seq Data.
Wang Y; Song X; Xu T
Curr Gene Ther; 2021; 21(3):258-269. PubMed ID: 33573552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
